Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Símbolo de cotizaciónEOLS
Nombre de la empresaEvolus Inc
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMr. David Moatazedi
Número de empleados332
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 08
Dirección520 Newport Center Dr Ste 1200
CiudadNEWPORT BEACH
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92660-7022
Teléfono19492844555
Sitio Webhttps://www.evolus.com/
Símbolo de cotizaciónEOLS
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMr. David Moatazedi
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos